Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeElixir MedicalElixir Medical to Release Five-year DESolve Nx Trial Data, Showcase Next-Generation Coronary...

Elixir Medical to Release Five-year DESolve Nx Trial Data, Showcase Next-Generation Coronary and SFA Bioresorbable Scaffold Systems at EuroPCR 2017


Long-term 5-year clinical follow-up data for the DESolve® Novolimus eluting coronary scaffold system, 6-month clinical and imaging data for the 120 µm thin-strut DESolve Cx Novolimus eluting coronary bioresorbable scaffold system, and initial clinical results of the PRAVA Bioresorbable scaffold system for SFA in the peripheral vasculature

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will release at EuroPCR in Paris the long-term 5-year clinical follow-up data for the DESolve® Novolimus eluting coronary scaffold system, 6-month clinical and imaging data for the 120 µm thin-strut DESolve Cx Novolimus eluting coronary bioresorbable scaffold system, and initial clinical results of the PRAVA Bioresorbable scaffold system for SFA in the peripheral vasculature. EuroPCR is the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.

@ElixirMed to present 5yr DESolve Nx Trial Data, Next-Gen Coronary & SFA Bioresorbable Scaffold Systems #EuroPCR2017

Tweet this

Following are some of the highlights of Elixir Medical’s scientific sessions at EuroPCR (in chronological order) at the Palais Des Congres de Paris in Central European Summer Time (CEST):

Tuesday, May 16

12:30, Room 351

Multicentre evaluation of a novel 120µm DESolve Cx BRS: first report of six-month clinical and imaging endpoints
• Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

12:45, Room 351

Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and four-year clinical and imaging results
• Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium

Thursday, May 18

10:41, Room Maillot, Level 2

Elixir Medical DESAPPEAR SFA Study – Initial clinical experience with the PRAVA bioresorbable scaffold system
• Koen Deloose, MD, AZ St Blasius Hospital, Dendermonde, Belgium

Friday, May 19

10:30, Room 253

Multicentre, post-marketing evaluation of the Elixir DESolve Novolimus-Eluting coronary BRS system: 12M results for the DESolve PMCF study
• Ricardo Costa, MD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company’s next-generation drug-eluting stent systems and bioresorbable coronary scaffolds are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy